GIST Support International - logo

GIST Support International - Current Trials for GIST Cancer
GIST Imagery

Current Trials for GIST Cancer

Current clinical trials for GIST (gastrointestinal stromal tumor) are linkable entries in the list below, grouped by the type of drug being evaluated, plus drug combinations.

For more information about a drug, see its named page under our Emerging Treatments tab.


Maps of Trial Locations

When you click this link you will see a world map of GIST cancer trials at the website.  In countries where there are trials you will see a small white block with a black number indicating how many trials are open there.  Click the black number to zoom in on the geographic area of your choice.  For example, if you click on the USA or Europe, another map will open showing trials in each state or country.  Click again on the state or country of your choice to see which trials are available there.  NOTE that some trials listed in the table below will NOT appear on this map if GIST is not specifically listed in the trial protocol; for example, trials for any solid tumor may not appear. 


Current Trials by Drug Target

Clinical trials for GIST cancer are listed below according to the class of drug being tested (the target of the drug).  For each drug listed under each category, click "Trials at" to see the open trials relevant to GIST patients at the website

NOTE:  Drugs that are already FDA-approved for other cancers may be prescribed at the discretion of a physician outside of a clinical trial.  These drugs are indicated in the list below by "brand name" following the chemical name.

Tyrosine Kinase Inhibitors of KIT and/or PDGFRA 

Nilotinib (brand name Tasigna):   Trial at Fox-Chase  Trials at

Sorafenib (brand name Nexavar):  Trials at

Pazopanib (brand name Votrient): Trials at

Dasatinib (brand name Sprycel):  Trials at

Masitinib (AB1010): Trials at

Regorafenib:  Trials at

Crenolanib  (CP-868,596): Trials at

OSI-930Trials at

Cediranib (AZD2171)Trials at

Amuvatinib (MP470): Trials at 

Dovitinib (TKI258) : Trials at

DCC-2618: (trial expected to open) Trials at


Biologic Inhibitors of KIT or PDGFRA

Olaratumab (IMC-3G3):  Trials at


HSP90 Inhibitors

Ganetespib STA-9090: Trials at

Retaspimycin (IPI-504): Trials at

Tanespimycin (17-AAG, KOS-953): Trials at

SNX-5422: Trials at

AUY922: Trials at

AT13387: Trials at


Inhibitors of Pathways Downstream of KIT & PDGFR

RAS/RAF/MEK/ERK/MAPK inhibitors:

XL281Trials at

RDEA119Trials at 

GDC-0973 (XL518):  Trials at

Selumetinib (AZD6244): Trials at

BAY86-9766Trials at


AKT inhibitors: 

perifosineTrials at

XL418Trials at

mTOR inhibitors

everolimus (RAD001):  Trials at

sirolimus (brand name Rapamune):  Trials at

temsirolimus (brand name Torisel):  Trials at

deforolimus AP23573:  Trials at

PF-04691502Trials at


PI3K inhibitors

BEZ235Trials at

SF1126Trials at

XL147Trials at

XL765 (also inhibits mTOR):  Trials at

PX-866Trials at

GDC-0941 bismesylateTrials at

GDC-0980 (also inhibits mTOR):  Trials at

PF-04691502Trials at


BYL719:  Trials at

Buparlisib (BKM120):  Trials at


Cell Cycle Inhibitors

Vorinostat (brand name Zolinza):  Trials at

Ixabepilone (brand name Ixempra):  Trials at

CUDC101Trials at

PanobinostatTrials at

Insulin-like Growth Factor Pathway Inhibitors

BIIB022Trials at

AMG 479Trials at

MK0646Trials at

Figitumumab (CP-751,871):  Trials at

Linsitinib (OSI-906):  Trials at

XL228Trials at

Cixutumumab (IMC-A12):  Trials at

MEDI-573Trials at


This page is always under revision, and more trials will be added as they are identified. 


back to top